Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

키워드

참고문헌 (47)

1. Lazo M, "The epidemiology of nonalcoholic fatty liver disease: a global perspective", Semin Liver Dis, 28, pp.339~350 (2008)
2. 박영진, "Development and validation of a simple index system to predict nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 17(1), pp.19~26 (2011), 대한간학회
3. Park SH, "Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults", J Gastroenterol Hepatol, 21, pp.138~143 (2006)
4. Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
5. Marchesini G, "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
6. Sanyal AJ, "American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease", Gastroenterology, 123, pp.1705~1725 (2002)
7. Brunt EM, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
8. Ekstedt M, "Long-term follow-up of patients with NAFLD and elevated liver enzymes", Hepatology, 44, pp.865~873 (2006)
9. Matteoni CA, "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
10. Adams LA, "The natural history of nonalcoholic fatty liver disease: a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
11. Wong VW, "Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years", Gut, 59, pp.969~974 (2010)
12. Starley BQ, "Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection", Hepatology, 51, pp.1820~1832 (2010)
13. Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
14. Fontana RJ, "Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C", Gastroenterology, 138, pp.2321~2331 (2010)
15. Ratziu V, "Sampling variability of liver biopsy in nonalcoholic fatty liver disease", Gastroenterology, 128, pp.1898~1906 (2005)
16. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
17. Kim CW, "Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men", Metabolism, 61, pp.1182~1188 (2012)
18. Kowdley KV, "Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease", Hepatology, 55, pp.77~85 (2012)
19. Feldstein AE, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study", Hepatology, 50, pp.1072~1078 (2009)
20. Milner KL, "Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease", Hepatology, 49, pp.1926~1934 (2009)
21. Shen J, "Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers", J Hepatol, 56, pp.1363~1370 (2012)
22. Li X, "Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis", Hepatology, 51, pp.1865~1866 (2010)
23. Li H, "Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride", J Hepatol, 53, pp.934~940 (2010)
24. Assy N, "Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD)", Gut, 54, pp.729~ (2005)
25. Bonnefont-Rousselot D, "Blood oxidative stress markers are unreliable markers of hepatic steatosis", Aliment Pharmacol Ther, 23, pp.91~98 (2006)
26. Shimada M, "Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis", Am J Gastroenterol, 102, pp.1931~1938 (2007)
27. Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)
28. Feldstein AE, "Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis", Gastroenterology, 125, pp.437~443 (2003)
29. Danial NN, "Cell death: critical control points", Cell, 116, pp.205~219 (2004)
30. Wieckowska A, "In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease", Hepatology, 44, pp.27~33 (2006)
31. Haffner SM, "The homeostasis model in the San Antonio Heart Study", Diabetes Care, 20, pp.1087~1092 (1997)
32. Alberti KG, "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
33. Younossi ZM, "Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality", Hepatology, 53, pp.1874~1882 (2011)
34. Rafiq N, "Long-term follow-up of patients with nonalcoholic fatty liver", Clin Gastroenterol Hepatol, 7, pp.234~238 (2009)
35. Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis", Hepatology, 54, pp.344~353 (2011)
36. Tsutsui M, "Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels", J Clin Gastroenterol, 44, pp.440~447 (2010)
37. Neuschwander-Tetri BA, "Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease", Hepatology, 52, pp.913~924 (2010)
38. Zatloukal K, "From Mallory to Mallory-Denk bodies: what, how and why?", Exp Cell Res, 313, pp.2033~2049 (2007)
39. Feldstein AE, "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway", Hepatology, 40, pp.185~194 (2004)
40. Musso G, "Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity", Ann Med, 43, pp.617~649 (2011)
41. Wieckowska A, "Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future", Hepatology, 46, pp.582~589 (2007)
42. Chalasani N, "The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology", Gastroenterology, 142, pp.1592~1609 (2012)
43. Bell H, "Serum ferritin and transferrin saturation in patients with chronic alcoholic and nonalcoholic liver diseases", J Intern Med, 236, pp.315~322 (1994)
44. Turlin B, "Histologic features of the liver in insulin resistanceassociated iron overload. A study of 139 patients", Am J Clin Pathol, 116, pp.263~270 (2001)
45. Manousou P, "Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients", Liver Int, 31, pp.730~739 (2011)
46. Zelber-Sagi S, "NAFLD and hyperinsulinemia are major determinants of serum ferritin levels", J Hepatol, 46, pp.700~707 (2007)
47. Fracanzani AL, "Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes", Hepatology, 48, pp.792~798 (2008)

관련 논문AI추천